Over 50 molecules in different stages of development in fields such as oncology, hematology, immunology, cardiovascular. More than 40 molecules in development and over 140 clinical trials active in Italy. These are the numbers of Bristol Myers Squibb srl now that the acquisition by incorporation of Celgene srl has been concluded, also in Italy. “It is an exciting moment in the history of our company – explains Emma Charles, General Manager Bristol Myers Squibb Srl -. With the acquisition of Celgene, Bristol Myers Squibb’s pipeline is now among the largest and most diverse in the pharmaceutical world. In particular, we operate in therapeutic areas where the need for new drugs or alternative therapies to existing ones is high “.
Bristol Myers Squibb continues to invest in innovation in the future by partnering with the scientific community, academia, institutions and patient organizations, to ensure therapeutic innovation translates into better clinical outcomes for patients. “We have a history of scientific excellence focused on the research and development of cutting-edge therapies – says Emma Charles -. Pioneers in the discovery of immuno-oncology, we have revolutionized the way cancer is treated, improving patients’ long-term survival and quality of life. We have redefined the horizons of multiple myeloma treatment by changing the natural history of the disease with a broad portfolio of innovative drugs and are now engaged in the field of cell therapies. For over 30 years we have been bringing innovation to cardiovascular pathologies and we continue to be pioneers in immunology, with new therapeutic approaches “.